CervoMed Inc.

CervoMed Inc.

CRVO·NASDAQ

$5.50

-0.36%
HealthcareBiotechnology

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

At a Glance

Live Snapshot
Market Cap$50.89M
EPS-2.0200
P/E Ratio-1.16
Earnings Date03/16/2026

crvo

Other Current Liabilities

Last Annual Value

919.08K

3-Year CAGR

141%

5-Year CAGR

39%

10-Year CAGR

25%

CervoMed Inc.

CervoMed Inc. Competitors Analysis of Other Current Liabilities

CRVO · NASDAQ
CompanyOther Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
CRVO logo
CervoMed Inc.
NASDAQ:CRVO
919.08K
-6.2%69.4%6.8% 
23.99M
75.7%37.5%N/A
2.31M
-58.0%-41.7%-21.0%
2.35M
-20.7%7.8%N/A
ACET logo
Adicet Bio, Inc.
NASDAQ:ACET
13.61M
25.2%27.6%-12.1%
CLNN logo
Clene Inc.
NASDAQ:CLNN
5.00M
33.1%57.3%N/A
33.64M
110.1%190.4%N/A
-1.03M
N/AN/AN/A
9.97M
N/AN/AN/A
7.86M
20.4%15.7%N/A
VXRT logo
Vaxart, Inc.
NASDAQ:VXRT
-2.98M
N/AN/AN/A
CervoMed Inc.

CervoMed Inc. Fair Value Envelope

CRVO · NASDAQ

Our analysis suggests that CRVO has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.5, this represents a potential HIDDEN relative to our calculated worth for CervoMed Inc..

Intrinsic Value
Current Price: $5.5